Novo Nordisk Shakes Up Leadership Amid Strategic Dispute

Novo Nordisk is undergoing significant leadership changes, including the replacement of its chair and six independent directors, due to a strategic disagreement with the Novo Nordisk Foundation. The new appointees bring extensive experience from notable companies, aiming to bolster the company's strategic direction and revitalize sales.

Novo Nordisk is set for a major boardroom shakeup as it prepares to replace Chair Helge Lund and six independent directors following strategic disagreements with the controlling Novo Nordisk Foundation. The changes are scheduled for an extraordinary general meeting on November 14.

These leadership adjustments follow Mike Doustdar's appointment as CEO in August, tasked with reviving sales of the weight-loss drug Wegovy. Key board members, including Kasim Kutay and several employee-elected representatives, will remain.

Notable appointees include Lars Rebien Sørensen as Chair, bringing his prior experience as President and CEO of Novo Nordisk from 2000 to 2016. Other appointed members have held significant roles in industry-leading companies, highlighting a strategic focus on strengthening leadership.

(With inputs from agencies.)